| INTRODUCTION
Upper respiratory infection (URI) is a common and serious problem in cats in boarding facilities, animal hospitals, and shelters. Unfortunately, few quickly effective options are available for preventing these infections in newly exposed cats. Immunoprophylaxis may be most effective if focused at the likely portal of pathogen entry. The upper respiratory tract is the site of entry for several important respiratory pathogens of cats, consisting of a diverse array of viral and bacterial organisms, including feline herpesvirus 1 (FHV-1), calicivirus, Mycoplasma sp., Bordetella bronchiseptica, and Chlamydia felis. interferons, tumor necrosis factor alpha (TNF-α), and interleukin 12 (IL-12) and chemokines such as monocyte chemoattractant protein 1 and IL-8 that recruit monocytes, T cells, and neutrophils. Local activation of innate immune responses may create an environment that is less susceptible to viral entry and replication or to bacterial invasion and colonization. 7 Clinically, such an immune protective effect could be manifested as either partial or complete protection from infection or as a decrease in the severity and duration of clinical signs of illness, along with decreased viral or bacterial shedding.
One potential solution to the problem of complex upper respiratory tract infections in cats would be an immunotherapeutic agent capable of inducing nonspecific immune activation at mucosal surfaces in the oropharynx, such as liposome-toll-like receptor complexes (LTC). These complexes have been shown previously to induce strong nonspecific protection from lethal bacterial and viral respiratory tract infections after intranasal administration in several different mouse infection models. [8] [9] [10] [11] [12] In addition, we demonstrated induction of therapeutic immune responses in cats with chronic rhinitis after parenteral administration of LTC. 13 Therefore, we reasoned that immune stimulatory complexes could be further optimized for mucosal delivery and generation of local mucosal immune responses in the upper respiratory tract of cats. Therefore, the original LTC formulation was modified to improve its innate immune stimulatory potency and to improve adhesion and contact time with mucosal surfaces.
In the present study, the immune activating properties of modified LTC were evaluated in cats. 12, 14 The modified LTC consisted of cationic liposomes formulated with 2 TLR agonists: polyinosinic-polycytidylic acid (poly I:C), as a TLR3, retinoic acid-inducible gene I, melanoma differentiation-associated protein 5 agonist, and noncoding plasmid DNA (pDNA), as a TLR9 agonist rich in cytosine-guanine. In addition, the modified LTC contained a mucosal adhesive agent (carboxymethylcellulose) to increase adhesion to mucosal cell surfaces. We also assessed cytokine and cell activation responses by feline leukocytes in vitro and also assessed the local mucosal immune responses to topical administration of LTC in healthy cats.
| MATERIALS AND METHODS

| Preparation of liposome-TLR agonist complexes for mucosal immune stimulation
Liposomes were prepared by dissolving the cationic lipid, 1,2-dioleoyl-3-trimentylammonium-propane (DOTAP) and cholesterol (Avanti Polar Lipids, Alabaster, AL) in chloroform, and the solution was dried overnight in a vacuum desiccator to a thin film. The lipids were rehydrated in 5% sterile dextrose in water at 50 C as described previously. 12, 14 Poly I:C (InVivoGen, San Diego, California) and pDNA (noncoding commercial plasmid PCR2.1) Thermo Fisher Scientific, Waltham, MA were added to form liposome complexes, as reported previously. 12, 14 The endotoxin content of the plasmid was between 0.04 and 0.25 EU/μg.
Carboxymethylcellulose (Sigma-Aldrich, St. Louis, Missouri) was added to the LTCs to increase mucosal adhesion. In studies in which fluorescent LTCs were delivered, the liposomes were formulated to contain 10% (vol/vol) Topfluor-labeled cholesterol (Avanti Polar Lipids). well) in triplicate wells of PBMC in 100 μL complete medium, with careful mixing, and then the cells were incubated for an additional 48 hours.
| Animal studies
Conditioned medium was collected for IFN-γ assay, and cells were collected for flow cytometric analysis of activation markers (see below) and for analysis of cytokine gene expression by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) (see below). Assays were repeated at least twice, using PBMC from different donor animals.
| Quantitative RT-PCR analysis of cytokine gene expression in vitro
Ribonucleic acid was extracted from PBMC incubated for 48 hours with LTC, as noted above, and expression of IL-1, IL-12, IFN-α, IFN-γ, and TNF-α genes was determined using quantitative RT-PCR. Briefly, RNA was isolated and reverse transcribed using a commercial kit (Qiagen, Germantown, Maryland), and the complementary DNA then was amplified using Cyber green primers (Bio-Rad, Hercules, California) using a qPCR MX3000p system instrument (Agilent, Santa Clara, California).
Cytokine transcript copy numbers were determined by quantitative RT-PCR, as noted previously. 
| Preparation and analysis of nasal and pharyngeal samples
Swabs were collected from the distal oropharynx and immediately placed in 2 mL of complete tissue culture medium in 15 mL polypropylene tubes on ice. The samples were lightly vortexed to free cells from the swabs. Fluid was transferred to a new tube, and 2 mL of PBS was added to the empty tube containing the swab, vortexed again, and pooled with the first sample. The sample then was filtered using a 70 μm cell strainer (Celltreat, Pepperell, Massachusetts) to remove debris and mucus. Samples were centrifuged, the cell pellets were resuspended in 0.5 mL of PBS, and the cells were counted.
Nasal lavage samples were filtered, washed, centrifuged, resuspended, and counted in the same fashion as for oropharyngeal swab samples. Cells were stained in the same manner as described for PBMC, and equal numbers were analyzed by flow cytometry to determine the cell type and activation.
| Confocal microscopy
Monocyte-derived macrophages were generated from cat PBMC by incubation of plastic adherent monocytes with 10 ng/mL human recombinant macrophage colony stimulating factor for 5 days. The macrophages that were generated were then incubated with 0. 
| Statistical methods
Statistical comparisons between data sets with 2 treatment groups were performed using the nonparametric Mann-Whitney test. Comparisons among 3 or more groups were performed using analysis of variance, followed by the Tukey multiple means post-test. Analyses were performed using Prism6 software (GraphPad, La Jolla, California).
For all analyses, statistical significance was set at P < .05.
3 | RESULTS 
| B cells, T cells, and monocytes from feline PBMC activated by LTC in vitro
| LTC treatment triggers IFN-γ secretion by PBMC
Supernatants were collected from PBMC after 48 hours stimulation with LTC, for analysis of IFN-γ production ( Figure 3 ). Liposome-TLR complexes treatment stimulated a dose-dependent, significant secretion of IFN-γ secretion, as determined by ELISA analysis of supernatants.
| Uptake of labeled LTC by macrophages in vitro
Monocyte-derived macrophages were generated from PBMC of cats by 
| Retention of labeled LTC by cells in the oropharynx and nasal cavity
Seven healthy adult cats were given 0.1 mL of labeled LTC bilaterally into the nostrils and 0.6 mL PO. Nasal lavage and throat swab samples MHCII expression by gated CD14+ monocytes. *, P < .05, **, P < .01 and ***, P < .005. LTC, liposome-toll-like receptor complexes; OX40, tumor necrosis factor receptor superfamily, member 4; PBMC, peripheral blood mononuclear cells Figure 5A ) and in throat swab cells (oropharynx, Figure 5B ). Peak uptake of LTC-labeled cells in the nasal lavage samples occurred 6 hours after LTC administration, whereas in the oropharynx peak of LTC uptake occurred 20 hours after administration.
| Intranasal and PO administration of LTC triggers influx of inflammatory leukocytes to mucosal surfaces
Cells from the nasal cavity or oropharynx were obtained by nasal lavage or swabbing the back of the throat, respectively, as described The neutrophil population was essentially unchanged throughout the study time course in both the nose and the oropharynx after LTC administration ( Figure 6 ). oropharynx. The recruitment of monocytes by LTC could be attributed to production of the chemokine CCL2, which has been noted previously after treatment with LTC. 11 In contrast, the transient disappearance of T cells from mucosal sites after LTC administration most likely could be attributed to transient redistribution of T cells after adherence to capillary blood vessels or migration into tissues. A similar effect has been observed previously in dogs treated systemically with LTC. 24 In support of transient redistribution, we observed that CD5 + T lymphocytes were rapidly restored in mucosal sites within 72 hours after LTC administration.
We also observed distinct differences in resident immune cell populations in the nasal cavity and oropharynx, especially with respect to the density of mucosal T cells. For example, the oropharynx was found to be highly enriched in mucosal CD5 + T cells, whereas T cells were much less numerous in the nasal cavity (see Figure 6 ). These dif- 
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